Results for: Marburg virus

The Sabin Vaccine Institute has expanded its clinical trial for an investigational Marburg virus vaccine in Rwanda, increasing the number of participants to include mine workers at risk of exposure. The expanded trial aims to assess the vaccine’s safety, immunogenicity, and efficacy. This initiative comes amidst a large-scale Marburg outbreak in Rwanda, where over 1,500 frontline workers have already been vaccinated with the Sabin vaccine.

The Marburg virus, known for its high fatality rate, has emerged in Rwanda, prompting a global health response. Quarantine measures, health screenings, and public education campaigns are being implemented to contain the virus and prevent further spread. The outbreak has highlighted the importance of rapid response, collaboration, and ongoing research into effective treatments and vaccines.